GlobeStar Therapeutics Co. (OTCMKTS:GSTC) Sees Large Drop in Short Interest

GlobeStar Therapeutics Co. (OTCMKTS:GSTCGet Free Report) was the recipient of a significant decline in short interest in February. As of February 15th, there was short interest totalling 3,200 shares, a decline of 91.0% from the January 31st total of 35,600 shares. Based on an average trading volume of 10,934,400 shares, the days-to-cover ratio is currently 0.0 days.

GlobeStar Therapeutics Stock Performance

Shares of OTCMKTS GSTC traded up $0.00 during midday trading on Thursday, hitting $0.00. 2,027,777 shares of the stock traded hands, compared to its average volume of 4,216,384. GlobeStar Therapeutics has a one year low of $0.00 and a one year high of $0.00.

GlobeStar Therapeutics Company Profile

(Get Free Report)

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc and changed its name to GlobeStar Therapeutics Corporation in July 2021.

Read More

Receive News & Ratings for GlobeStar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlobeStar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.